LEXSTON LIFE SCIENCES CORP. ANNOUNCES UPGRADE TO OTCQB MARKET IN THE UNITED STATES
Vancouver, British Columbia, November 15, 2021. Lexston Life Sciences Corp. (CSE: LEXT) (OTCQB: LEXTF) (the “Company” or “Lexston”) is pleased to announce that after successfully completing the application process, the Company has received approval from OTC Markets Group Inc. for its common shares to begin trading on the OTCQB Market (“OTCQB”) beginning at market open on November 12, 2021 under the symbol “LEXTF”. The Company’s common shares will remain listed on the CSE in Canada under the ticker symbol “LEXT”.
OTC Markets Group Inc., located in New York, N.Y., operates the world’s largest electronic inter-dealer quotation system for broker dealers to trade over 10,000 securities. The OTCQB is a transparent trading quotation system for broker dealers to trade over 10,000 securities. Lexston’s quotation and trading on the OTCQB provides investors the opportunity to benefit from streamlined market standards which enhance the availability of information to the general public, enabling greater transparency. North American and international investors can find Real-Time level 2 quotes (denominated in US dollars) and market information for Lexston Life Sciences Corp. common shares at https://www.otcmarkets.com/stock/LEXTF/quote along with current company news.
The Company would like to thank Nikolaos Galanopoulos of Galanopoulos & Company, the corporate securities law firm that advised Lexston in relation to the OTCQB application process.
About Lexston Life Sciences Corp.
Lexston Life Sciences Corp. (“Lexston”) is a Canadian biotechnology company providing cannabis testing and research services. Lexston is also in the process of securing licensing under the exemptions prescribed by section 56 of the Controlled Drugs and Substances Act (Canada) to enable the expansion of prescribed by section 56 of the Controlled Drugs and Substances Act (Canada) to enable the expansion of psychedelic molecules in the lab and point of care. Lexston intends to develop and validate methods for standardized manufacturing of plant derived psychedelics in support of burgeoning trials in the ﬁeld of mental health and wellness.
On Behalf of the Board of Directors
LEXSTON LIFE SCIENCES CORP.
Chief Executive Oﬃcer
Telephone: (604) 928-8913
Neither the Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.
929 Mainland Street Vancouver, BC V6B 1S3
This news release contains forward-looking statements and information within the meaning of applicable securities legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance, or achievements of LEXT to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this news release.
Risks, uncertainties, and other factors involved with forward-looking information could cause actual events, results, performance, prospects, and opportunities to differ materially from those expressed or implied by such forward-looking information. The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.